Pharmacokinetics of ferric bepectate—a new intravenous iron drug for treating iron deficiency
Open Access
- 6 March 2019
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 125 (2), 133-141
- https://doi.org/10.1111/bcpt.13219
Abstract
IV iron is indicated in clinical conditions, where rapid anaemia alleviation and repletion of iron stores are required. The acute toxicity of IV iron is ascribed to the presence of labile iron in plasma. Thus, shorter plasma residence time might improve the safety profile, even for compounds holding‐on the iron tightly. In this single‐centre, open‐label, single‐dose escalation study, we evaluated the elimination kinetics of ferric bepectate (FBP) compared to those of ferric carboxymaltose (FCM). Thirty‐three iron‐depleted anaemic patients who had undergone cardiac surgery were included and received 200, 500 or 1500 mg FBP or 500 mg FCM. Plasma drug curves were subjected to model‐free analysis. Because saturation kinetics was found, a compartmental model with limited elimination capacity was applied. Urinary iron excretion was also analysed. The initial non‐compartmental analysis revealed an increasing AUC/dose ratio for FBP. For both drugs, the central distribution compartment corresponded to plasma volume, and elimination followed Michaelis‐Menten saturation kinetics. Maximal elimination rates (Vmax) were 224 mg/hr and 81 mg/hr for FBP 500 mg and FCM 500 mg, respectively; drug concentrations at half Vmax (Km), 99 mg/L and 212 mg/L, respectively; and terminal plasma half‐life (T½), 3.05 hr and 8.96 hr, respectively. Both drugs were equally effective in eliciting an early ferritin rise. Urinary iron excretion was measurable in all patients receiving FCM but not in those receiving FBP, which was well tolerated. Intravenous iron drugs are subject to capacity‐limited elimination with different saturation thresholds. Urinary iron excretion can be used as a surrogate for labile plasma iron.Keywords
Funding Information
- Iron4u
This publication has 39 references indexed in Scilit:
- Labile iron in cells and body fluids: physiology, pathology, and pharmacologyFrontiers in Pharmacology, 2014
- A systematic analysis of global anemia burden from 1990 to 2010Blood, 2014
- The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: Insights into the potential of various iron therapies to induce oxidative and nitrosative stressFree Radical Biology & Medicine, 2013
- Tolerability of different oral iron supplements: a systematic reviewCurrent Medical Research and Opinion, 2013
- Pharmacokinetics of Iron Isomaltoside1000 in Patients with Stage 5 Chronic Kidney Disease on Dialysis TherapyJournal of Drug Metabolism and Toxicology, 2013
- Pharmacokinetics of iron isomaltoside 1000 in patients with inflammatory bowel diseaseDrug Design, Development and Therapy, 2012
- A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer®), a new intravenous iron preparation and its clinical implicationsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2011
- Disorders of iron metabolism. Part II: iron deficiency and iron overloadJournal of Clinical Pathology, 2010
- Pharmacokinetics, safety and tolerability of intravenous ferric carboxymaltose: a dose-escalation study in volunteers with mild iron-deficiency anaemiaArzneimittelforschung, 2010
- Urinary albumin, transferrin and iron excretion in diabetic patientsKidney International, 1991